These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9422838)

  • 1. Heparin dosing for percutaneous coronary angioplasty: use of body surface area to improve initial activated clotting time values.
    Pesola GR; Pesola DA
    Clin Cardiol; 1997 Dec; 20(12):1006-9. PubMed ID: 9422838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous transluminal coronary angioplasty: comparison of arterial vs. venous activated clotting time.
    Pesola GR; Johnson A; Pesola DA
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):140-4. PubMed ID: 8808068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal heparinization in coronary angioplasty--how much heparin is really warranted?
    Kaluski E; Krakover R; Cotter G; Hendler A; Zyssman I; Milovanov O; Blatt A; Zimmerman E; Goldstein E; Nahman V; Vered Z
    Am J Cardiol; 2000 Apr; 85(8):953-6. PubMed ID: 10760333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty.
    Helft G; Choktron S; Beygui F; Le Feuvre C; Elalamy I; Metzger JP; Vacheron A; Samama MM
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):329-31. PubMed ID: 9829899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.
    Marmur JD; Anand SX; Bagga RS; Fareed J; Pan CM; Sharma SK; Richard MF
    J Am Coll Cardiol; 2003 Feb; 41(3):394-402. PubMed ID: 12575965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedside coagulometry during intravenous heparin therapy after coronary angioplasty.
    Schroeder AP; Knudsen LL; Husted SE; Knudsen L; Ingerslev J
    J Thromb Thrombolysis; 2001 Oct; 12(2):157-63. PubMed ID: 11729367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
    J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty.
    Rath B; Bennett DH
    Br Heart J; 1990 Jan; 63(1):18-21. PubMed ID: 2178656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More Effective Anticoagulation During Non-Cardiac Arterial Procedures Using Activated Clotting Time Guided Heparin Administration.
    Doganer O; Wiersema AM; Pierie M; Blankensteijn JD; Yeung KK; Jongkind V
    Ann Vasc Surg; 2021 Oct; 76():378-388. PubMed ID: 33951528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty.
    Wilson JM; Dougherty KG; Ellis KO; Ferguson JJ
    Cathet Cardiovasc Diagn; 1995 Jan; 34(1):1-5. PubMed ID: 7728844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
    Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of race (Asian, African-American, European-American, and Hispanic) to activated clotting time after weight-adjusted bolus of heparin during percutaneous coronary intervention.
    Shimada YJ; Nakra NC; Fox JT; Kanei Y
    Am J Cardiol; 2010 Mar; 105(5):629-32. PubMed ID: 20185008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of activated clotting time (ACT) to optimize heparinization during coronary angioplasty. The nursing personnel of the Hemodynamics Laboratory].
    Dellavalle A; Steffenino G; Ribichini F; Russo P; Conte L; Conte E; Uslenghi E
    G Ital Cardiol; 1995 Apr; 25(4):445-51. PubMed ID: 7642051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated clotting-time variability in patients undergoing coronary angioplasty.
    Warner MF; Mian MS; Missri JC
    Clin Cardiol; 1994 Jul; 17(7):372-4. PubMed ID: 8088023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty.
    Bittl JA; Ahmed WH
    Am J Cardiol; 1998 Oct; 82(8B):50P-56P. PubMed ID: 9809892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention.
    Dauerman HL; Ball SA; Goldberg RJ; Desourdy MA; Furman MI
    J Thromb Thrombolysis; 2002 Jun; 13(3):127-32. PubMed ID: 12355028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Standardized Bolus of 5 000 IU of Heparin Does not Lead to Adequate Heparinization during Non-cardiac Arterial Procedures.
    Doganer O; Jongkind V; Blankensteijn JD; Yeung KK; Wiersema AM
    Ann Vasc Surg; 2021 Feb; 71():280-287. PubMed ID: 32768536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
    Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
    Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a national survey on anticoagulation for PTCA.
    Ferguson JJ; Dohmen P; Wilson JM; Vaughn WK; Khoshnevis R; Kmonicek P; McKinney AA; Plachetka JR
    J Invasive Cardiol; 1995 Jun; 7(5):136-41. PubMed ID: 10155096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.